Trial Profile
A Phase 2 Trial of Intratumoral EGFR Antisense DNA (BB-401) in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC) Who Have Failed All Available Standard Therapies
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Aug 2023
Price :
$35
*
At a glance
- Drugs BB-401 (Primary)
- Indications Carcinoma; Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors Benitec Biopharma
- 13 Apr 2020 Status changed from active, no longer recruiting to completed.
- 14 Jan 2020 Planned End Date changed from 19 Oct 2019 to 19 Oct 2020.
- 14 Jan 2020 Planned primary completion date changed from 12 Apr 2019 to 12 Jun 2020.